Publications

Detailed Information

ABSENCE OF SYMPTOM AND INTACT LIVER FUNCTION ARE POSITIVE PROGNOSTICATORS FOR PATIENTS UNDERGOING RADIOTHERAPY FOR LYMPH NODE METASTASIS FROM HEPATOCELLULAR CARCINOMA

DC Field Value Language
dc.contributor.authorKim, Kyubo-
dc.contributor.authorChie, Eui Kyu-
dc.contributor.authorKim, Won-
dc.contributor.authorKim, Yoon Jun-
dc.contributor.authorLee, Hyo-Suk-
dc.contributor.authorHa, Sung W.-
dc.contributor.authorYoon, Jung Hwan-
dc.date.accessioned2012-06-27T08:47:02Z-
dc.date.available2012-06-27T08:47:02Z-
dc.date.issued2010-11-01-
dc.identifier.citationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS; Vol.78 3; 729-734ko_KR
dc.identifier.issn0360-3016-
dc.identifier.urihttps://hdl.handle.net/10371/77657-
dc.description.abstractPurpose: The positive role of radiotherapy for patients with lymph node (LN) metastasis from hepatocellular carcinoma has recently been reported. The outcome and prognostic factors for these patients were analyzed. Methods and Materials: Between May 2004 and October 2007,38 patients with LN metastases from hepatocellular carcinoma underwent radiotherapy. The median age was 59 years (range, 42-81). The radiation dose was 35-56 Gy with a fraction size of 1.8-3 Gy, for a biologically effective dose of 43.75-67.2 Gy(10) (median, 59.0). The median follow-up period was 8 months. Results: The median survival time was 10 months. On univariate analysis, Child-Pugh class B (p = .0006), distant metastasis (p = .0095), symptoms related to metastatic LNs (p <.0001), and a biologically effective dose <60 Gy(10) (p = .0042) were significant prognostic factors predicting for poor overall survival. On multivariate analysis after adjustment using the Benjamini and Hochberg (false discovery rate) method, Child-Pugh class B (p = .04095) and the presence of symptoms (p = .04095) were associated with inferior overall survival. When patients were divided into three groups according to these two risk factors, the median survival for patients with no, either, or both risk factors was 20, 7, and 4 months, respectively (p <.0001). Conclusion: Patients with intact liver function and without related symptoms had the best prognosis when undergoing radiotherapy for LN metastasis from hepatocellular carcinoma. (C) 2010 Elsevier Inc.ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCIENCE INCko_KR
dc.subjectLymph node metastasisko_KR
dc.subjectLiver functionko_KR
dc.subjectHepatocellular carcinomako_KR
dc.subjectRadiotherapyko_KR
dc.subjectSymptomsko_KR
dc.titleABSENCE OF SYMPTOM AND INTACT LIVER FUNCTION ARE POSITIVE PROGNOSTICATORS FOR PATIENTS UNDERGOING RADIOTHERAPY FOR LYMPH NODE METASTASIS FROM HEPATOCELLULAR CARCINOMAko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김규보-
dc.contributor.AlternativeAuthor지의규-
dc.contributor.AlternativeAuthor김원-
dc.contributor.AlternativeAuthor김윤준-
dc.contributor.AlternativeAuthor윤정환-
dc.contributor.AlternativeAuthor이효석-
dc.contributor.AlternativeAuthor하성환-
dc.identifier.doi10.1016/j.ijrobp.2009.08.047-
dc.citation.journaltitleINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.description.citedreferenceCheng AL, 2009, LANCET ONCOL, V10, P25-
dc.description.citedreferenceSun HC, 2007, J SURG ONCOL, V96, P37, DOI 10.1002/jso.20772-
dc.description.citedreferenceYamashita H, 2007, J GASTROEN HEPATOL, V22, P523, DOI 10.1111/j.1440-1746.2006.04450.x-
dc.description.citedreferenceSeong J, 2007, INT J RADIAT ONCOL, V67, P1037, DOI 10.1016/j.ijrobp.2006.10.035-
dc.description.citedreferencePark YJ, 2006, J GASTROENTEROL, V41, P1099, DOI 10.1007/s00535-006-1895-x-
dc.description.citedreferenceYeo W, 2006, ANN ONCOL, V17, P1083, DOI 10.1093/annonc/mdl065-
dc.description.citedreferenceNanashima A, 2006, J GASTROENTEROL, V41, P250, DOI 10.1007/s00535-005-1751-4-
dc.description.citedreferenceZeng ZC, 2005, INT J RADIAT ONCOL, V63, P1067, DOI 10.1016/j.ijrobp.2005.03.058-
dc.description.citedreferenceHuang YH, 2005, J GASTROEN HEPATOL, V20, P765, DOI 10.1111/j.1400-1746.2005.03746.x-
dc.description.citedreferenceErcolani G, 2004, ANN SURG, V239, P202, DOI 10.1097/01.sla.0000109154.00020.e0-
dc.description.citedreferencePARK JW, 2004, KOREAN J HEPATOL, V10, P88-
dc.description.citedreferenceZeng ZC, 2004, HEPATO-GASTROENTEROL, V51, P201-
dc.description.citedreferenceLeung TWT, 2002, CANCER, V94, P1760, DOI 10.1002/cncr.10384-
dc.description.citedreferenceUenishi T, 2000, SURG TODAY, V30, P892-
dc.description.citedreferenceLlovet JM, 1999, SEMIN LIVER DIS, V19, P329-
dc.description.citedreferenceManghisi G, 1998, HEPATOLOGY, V28, P751-
dc.description.citedreferenceCoates A, 1997, EUR J CANCER, V33, P1025-
dc.description.citedreferenceDancey J, 1997, QUAL LIFE RES, V6, P151-
dc.description.citedreferenceRingdal GI, 1996, BRIT J CANCER, V73, P1594-
dc.description.citedreferenceCOX JD, 1995, INT J RADIAT ONCOL, V31, P1341-
dc.description.citedreferenceBENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289-
dc.description.citedreferenceKACZYNSKI J, 1995, ACTA ONCOL, V34, P43-
dc.description.citedreferenceBECKBORNHOLDT HP, 1994, RADIOTHER ONCOL, V33, P171-
dc.description.citedreferenceWATANABE J, 1994, JPN J CLIN ONCOL, V24, P37-
dc.description.citedreferenceUNE Y, 1994, SURG TODAY, V24, P606-
dc.description.citedreferenceOKUDA K, 1985, CANCER, V56, P918-
dc.description.citedreferenceKAPLAN EL, 1958, J AM STAT ASSOC, V53, P457-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share